MetaCap

Lycia Therapeutics (LYCA) vs Windward Bio Group (WWB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lycia Therapeutics is the larger company by market cap ($1.72 billion vs $1.45 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LYCA+5.99%WWB-14.79%
+7%-7%-22%
Nov 13, 20261 yearNov 20, 2026
LYCA+5.99%WWB-14.79%
+7%-4%-16%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LYCA versus WWB key metrics
MetricLYCAWWB
Share price$33.07$24.29
Market cap$1.72B$1.45B
1-day change+4.09%+1.15%
EPS (TTM)$-1.04$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$36.49$33.99
52-week low$22.19$18.35
Distance from 52-week high-9.37%-28.55%
Average volume432.72K434.33K
Shares outstanding52.09M59.58M
Employees3133
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Lycia Therapeutics

LYCA stock →

Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31 employees

About Windward Bio Group

WWB stock →

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees

LYCA vs WWB FAQ

Which is bigger, Lycia Therapeutics or Windward Bio Group?

Lycia Therapeutics (LYCA) is larger, with a market capitalization of $1.72B compared with $1.45B for Windward Bio Group (WWB).

Are Lycia Therapeutics and Windward Bio Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons